Pfizer (PFE) exceeded Street forecasts with its Q3 2025 results on Tuesday, thanks mainly to sales from its COVID vaccine ...
Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol ...
BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost optimization.
Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full ...
The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...
Pfizer and BioNTech have asked the Food and Drug Administration for emergency use authorization of their COVID-19 booster targeting omicron subvariants BA.4 and BA.5 and the original strain of the ...
The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general ...
Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) reported topline Phase 3 results for their LP.8.1-adapted monovalent COMIRNATY (2025-2026 Formula) in high-risk adults. Among 100 participants, the ...
Pfizer and BioNTech have begun a clinical trial for their Omicron-specific COVID-19 vaccine candidate, they announced in a news release on Tuesday. The study will evaluate the vaccine for safety, ...
The children's parents discussed their decision with ABC News. Three American siblings have received their first dose of the Pfizer-BioNTech COVID-19 vaccine as part of global clinical trials for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback